Selnoflast

Selnoflast (RO7486967), formerly somalix/RG6418/IZD334, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease[1][2][3][4][5]

[1]Vande Walle L, et al. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat Rev Drug Discov. 2023 Nov 29.|[2]Klughammer B, et al. A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis. Clin Transl Med. 2023 Nov;13(11):e1471. |[3]McManus RM, et al. NLRP3 inflammasome signalling in Alzheimer's disease[J]. Neuropharmacology. 2024 Jul 1;252:109941. |[4]Teske KA, et al. Interrogating direct NLRP3 engagement and functional inflammasome inhibition using cellular assays[J]. Cell Chem Biol. 2024 Feb 15;31(2):349-360.e6. |[5]Zhang L, et al. Role of NLRP3 inflammasome in central nervous system diseases[J]. Cell Biosci. 2024 Jun 7;14(1):75.